Director of Business Development (Southeast) | Leading fully integrated pharmaceutical R&D for global pharma 🌍 | Partner with a top drug discovery CRO to accelerate innovation and deliver breakthrough results 🚀!
Thrilled to share that Medicilon Inc. is at the forefront of cancer research with our Patient-Derived Xenograft Organoids (#PDXOs). These 3D models replicate tumor features with exceptional accuracy, bridging the gap between in vivo and in vitro studies. We've developed nine PDXO models for various cancers, ensuring high quality and reliability. If you're interested in learning more, feel free to reach out to me! #PDXO #organoid #models
Patient-Derived Xenograft Organoids (#PDXOs) are 3D organoid models derived from patient-derived xenograft (PDX) tumor tissues. Constructed using methods like those employed for patient-derived organoids (PDOs), PDXOs replicate the genetic, molecular, and structural features of the original tumors with exceptional accuracy. These models surpass traditional 2D cell cultures by preserving the complex internal architecture of tumors, offering superior predictive power for selecting clinically relevant in vivo models and expediting drug development. PDXOs effectively bridge the gap between in vivo PDX models and in vitro tumor studies, combining the strengths of both approaches. Applicable across various cancer types-including breast, colorectal, lung, and more-PDXOs serve as a valuable platform for investigating tumor heterogeneity, drug responses, resistance mechanisms, and metastasis. At Medicilon, we have successfully developed nine PDXO models encompassing colorectal, pancreatic, gastric, leukemia, and prostate cancers. Each model undergoes stringent quality control processes, including the removal of mouse-derived fibroblasts, ensuring stable passaging, and cryopreservation. Learn more: https://lnkd.in/g_yWH3MC As this field continues to advance, the transformative potential of PDXOs in cancer research and treatment is immense. #PDXO #models #3D #organoid
